• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统性生成胰腺癌患者来源的肿瘤模型。

Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer.

机构信息

Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, 69120 Heidelberg, Germany.

出版信息

Cells. 2019 Feb 10;8(2):142. doi: 10.3390/cells8020142.

DOI:10.3390/cells8020142
PMID:30744205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6406729/
Abstract

In highly aggressive malignancies like pancreatic cancer (PC), patient-derived tumor models can serve as disease-relevant models to understand disease-related biology as well as to guide clinical decision-making. In this study, we describe a two-step protocol allowing systematic establishment of patient-derived primary cultures from PC patient tumors. Initial xenotransplantation of surgically resected patient tumors (n = 134) into immunodeficient mice allows for efficient in vivo expansion of vital tumor cells and successful tumor expansion in 38% of patient tumors (51/134). Expansion xenografts closely recapitulate the histoarchitecture of their matching patients' primary tumors. Digestion of xenograft tumors and subsequent in vitro cultivation resulted in the successful generation of semi-adherent PC cultures of pure epithelial cell origin in 43.1% of the cases. The established primary cultures include diverse pathological types of PC: Pancreatic ductal adenocarcinoma (86.3%, 19/22), adenosquamous carcinoma (9.1%, 2/22) and ductal adenocarcinoma with oncocytic IPMN (4.5%, 1/22). We here provide a protocol to establish quality-controlled PC patient-derived primary cell cultures from heterogeneous PC patient tumors. In vitro preclinical models provide the basis for the identification and preclinical assessment of novel therapeutic opportunities targeting pancreatic cancer.

摘要

在胰腺癌 (PC) 等侵袭性极强的恶性肿瘤中,患者来源的肿瘤模型可以作为与疾病相关的模型,用于了解疾病相关的生物学特性,并为临床决策提供指导。在这项研究中,我们描述了一种两步法方案,可系统地从 PC 患者肿瘤中建立患者来源的原代培养物。将手术切除的患者肿瘤(n = 134)初始异种移植到免疫缺陷小鼠中,可有效地在体内扩增有活力的肿瘤细胞,并使 38%的患者肿瘤(51/134)成功扩增。扩增的异种移植物紧密重现了与其匹配的患者原发肿瘤的组织学结构。对异种移植物进行消化,并随后进行体外培养,在 43.1%的病例中成功地产生了纯上皮细胞来源的半贴壁 PC 培养物。所建立的原代培养物包括多种不同病理类型的 PC:胰腺导管腺癌 (86.3%,19/22)、腺鳞癌 (9.1%,2/22) 和伴嗜酸细胞性 IPMN 的导管腺癌 (4.5%,1/22)。我们在此提供了一种从异质性 PC 患者肿瘤中建立质量控制的 PC 患者来源原代细胞培养物的方案。体外临床前模型为鉴定和临床前评估针对胰腺癌的新型治疗机会提供了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/155b/6406729/104d14056e51/cells-08-00142-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/155b/6406729/ff2f8f37253d/cells-08-00142-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/155b/6406729/d147ceab7165/cells-08-00142-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/155b/6406729/104d14056e51/cells-08-00142-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/155b/6406729/ff2f8f37253d/cells-08-00142-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/155b/6406729/d147ceab7165/cells-08-00142-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/155b/6406729/104d14056e51/cells-08-00142-g003.jpg

相似文献

1
Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer.系统性生成胰腺癌患者来源的肿瘤模型。
Cells. 2019 Feb 10;8(2):142. doi: 10.3390/cells8020142.
2
Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.内镜超声引导下细针抽吸获得的临床前胰腺癌模型显示 KRAS 野生型肿瘤对 panitumumab 的敏感性。
Int J Cancer. 2017 May 15;140(10):2331-2343. doi: 10.1002/ijc.30648. Epub 2017 Feb 28.
3
Establishment and Analysis of a 3D Co-Culture Spheroid Model of Pancreatic Adenocarcinoma for Application in Drug Discovery.用于药物研发的胰腺癌三维共培养球体模型的建立与分析
Methods Mol Biol. 2019;1953:163-179. doi: 10.1007/978-1-4939-9145-7_11.
4
Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor.胰腺导管腺癌患者来源异种移植模型与相应原发肿瘤的代谢差异。
BMC Cancer. 2024 Apr 17;24(1):485. doi: 10.1186/s12885-024-12193-x.
5
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer.靶向胰腺癌中的DNA损伤反应与复制应激
Gastroenterology. 2021 Jan;160(1):362-377.e13. doi: 10.1053/j.gastro.2020.09.043. Epub 2020 Oct 9.
6
Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival.胰腺导管腺癌患者来源异种移植瘤中的肿瘤植入与不良临床病理特征及较差生存率相关。
PLoS One. 2017 Aug 30;12(8):e0182855. doi: 10.1371/journal.pone.0182855. eCollection 2017.
7
Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.CDK4/6抑制对胰腺癌患者来源模型的选择性影响。
Oncotarget. 2015 Jun 30;6(18):15788-801. doi: 10.18632/oncotarget.3819.
8
Development of Patient-Derived Tumor Xenograft Models.患者来源的肿瘤异种移植模型的建立。
Methods Mol Biol. 2019;1862:217-225. doi: 10.1007/978-1-4939-8769-6_15.
9
Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.针对神经调节蛋白 1(NRG1)/表皮生长因子受体 3(HER3)通路,使用抗神经调节蛋白 1 抗体抑制肿瘤细胞和肿瘤相关成纤维细胞,可抑制胰腺癌临床前模型中的肿瘤生长。
Cancer Lett. 2018 Sep 28;432:227-236. doi: 10.1016/j.canlet.2018.06.023. Epub 2018 Jun 20.
10
Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.新型胃癌患者来源异种移植瘤和细胞系的建立:原发肿瘤、患者来源异种移植瘤和细胞系来源异种移植瘤之间的病理比较。
Cells. 2019 Jun 14;8(6):585. doi: 10.3390/cells8060585.

引用本文的文献

1
Human papillomavirus-associated head and neck squamous cell carcinoma cells lose viability during triggered myocyte lineage differentiation.人乳头瘤病毒相关的头颈部鳞状细胞癌细胞在触发肌细胞谱系分化过程中丧失活力。
Cell Death Dis. 2024 Jul 19;15(7):517. doi: 10.1038/s41419-024-06867-4.
2
Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures.用于患者来源的胰腺癌培养物中溶瘤病毒治疗疗效的生物标志物筛选。
EBioMedicine. 2024 Jul;105:105219. doi: 10.1016/j.ebiom.2024.105219. Epub 2024 Jun 27.
3
A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors.

本文引用的文献

1
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.起源细胞模式主导了 33 种癌症类型的 10000 个肿瘤的分子分类。
Cell. 2018 Apr 5;173(2):291-304.e6. doi: 10.1016/j.cell.2018.03.022.
2
Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going.基质在胰腺癌吉西他滨内在耐药中的复杂作用:我们的现状和未来方向。
Exp Mol Med. 2017 Dec 1;49(12):e406. doi: 10.1038/emm.2017.255.
3
Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer.
一种基于载体编码的双特异性杀伤嵌合分子,用于利用病毒激活的自然杀伤细胞作为抗肿瘤效应细胞。
Cell Death Dis. 2023 Feb 10;14(2):104. doi: 10.1038/s41419-023-05624-3.
4
Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model.病毒疗法联合抗 PD-1 治疗在临床前 PDAC 模型中短暂重塑肿瘤免疫微环境并诱导抗肿瘤免疫。
Front Immunol. 2023 Jan 16;13:1096162. doi: 10.3389/fimmu.2022.1096162. eCollection 2022.
5
Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches.头颈癌的精准医学:基因组学与临床前研究方法
J Pers Med. 2022 May 24;12(6):854. doi: 10.3390/jpm12060854.
6
Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.在人胰腺癌类器官中进行药物筛选和基因组编辑可确定药物-基因相互作用及非标签治疗候选药物。
Cell Genom. 2022 Feb;2(2):100095. doi: 10.1016/j.xgen.2022.100095.
7
Engineering of biomaterials for tumor modeling.用于肿瘤建模的生物材料工程
Mater Today Adv. 2020 Dec;8. doi: 10.1016/j.mtadv.2020.100117. Epub 2020 Nov 12.
8
Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine.胰腺导管腺癌(PDAC)类器官:药物反应预测和个性化医疗之曙光。
Cancers (Basel). 2020 Sep 24;12(10):2750. doi: 10.3390/cancers12102750.
9
Polymer nanoparticle-assisted chemotherapy of pancreatic cancer.聚合物纳米颗粒辅助化疗胰腺癌
Ther Adv Med Oncol. 2020 May 8;12:1758835920915978. doi: 10.1177/1758835920915978. eCollection 2020.
10
Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study.吉非替尼在 EGFR 扩增耐药实体瘤中的应用:一项开放标签、单臂、单中心前瞻性探索性研究。
Target Oncol. 2020 Apr;15(2):185-192. doi: 10.1007/s11523-020-00706-0.
胰腺3D类器官:作为胰腺癌个性化医疗研究平台的现状与未来展望
Cell Mol Gastroenterol Hepatol. 2017 Dec 16;5(3):289-298. doi: 10.1016/j.jcmgh.2017.12.004. eCollection 2018 Mar.
4
Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts.基于患者来源异种移植的肿瘤-基质互作分析揭示的胰腺导管腺癌治疗靶点。
Cell Rep. 2017 Nov 28;21(9):2458-2470. doi: 10.1016/j.celrep.2017.11.003.
5
Patient-derived xenografts undergo mouse-specific tumor evolution.患者来源的异种移植瘤经历小鼠特异性肿瘤进化。
Nat Genet. 2017 Nov;49(11):1567-1575. doi: 10.1038/ng.3967. Epub 2017 Oct 9.
6
The Generation and Application of Patient-Derived Xenograft Model for Cancer Research.患者来源异种移植模型在癌症研究中的产生与应用。
Cancer Res Treat. 2018 Jan;50(1):1-10. doi: 10.4143/crt.2017.307. Epub 2017 Sep 13.
7
Preclinical models of pancreatic ductal adenocarcinoma.胰腺导管腺癌的临床前模型
Chin Clin Oncol. 2017 Jun;6(3):25. doi: 10.21037/cco.2017.06.15.
8
Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer.结直肠癌中肿瘤克隆起始细胞的遗传亚克隆结构
J Exp Med. 2017 Jul 3;214(7):2073-2088. doi: 10.1084/jem.20162017. Epub 2017 Jun 1.
9
Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts.人胰腺癌异种移植瘤中瞬时激活的肿瘤起始细胞克隆的演替
EMBO Mol Med. 2017 Jul;9(7):918-932. doi: 10.15252/emmm.201607354.
10
Current status and perspectives of patient-derived xenograft models in cancer research.患者来源异种移植模型在癌症研究中的现状与展望
J Hematol Oncol. 2017 May 12;10(1):106. doi: 10.1186/s13045-017-0470-7.